Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin

Clinical Cancer Research

Volumn 4, Issue 2, 1998, Pages 389-398

  Mechetner, Eugene ^a   Kyshtoobayeva, Ainura ^a   Zonis, Svetlana ^a   Kim, Hun ^a   Stroup, Robert ^a   Garcia, Roxanna ^a   Parker, Ricardo J ^a   Fruehauf, John P ^a  

^a Oncotech Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; PACLITAXEL;

ARTICLE; BREAST CANCER; CANCER RESISTANCE; CARCINOMA CELL; CHEMOSENSITIVITY; FLOW CYTOMETRY; GLUTATHIONE METABOLISM; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE SECTION; TREATMENT FAILURE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; P-GLYCOPROTEIN; PACLITAXEL; TUMOR CELLS, CULTURED;

EID: 0031936939     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Boring, C. C., Squires, T. S., Tong, T., and Montgomery, S. Cancer statistics, 1994. CA Cancer J. Chin., 44: 7-26, 1994.
2. Fisher, G. A., and Sikic, B. I. Drug resistance in clinical oncology and hematology. Hematol. Oncol. Clin. N. Am., 9(2): 1995.
3. Lehnert, M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur. J. Cancer, 32A: 912-920, 1996.
4. Roninson, I. B. (ed). Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. New York: Plenum Press, 1990.
5. Germann, U. A. P-Glycoprotein: a mediator of multidrug resistance in tumor cells. Eur. J. Cancer, 32A: 927-944, 1996.
6. Gottesman, M. M., and Pastan, I. Biochemistry of multidrug resistance mediated by multidrug transporter. Annu. Rev. Biochem., 62: 385-427, 1993.
7. Wallner, J., Depisch, D., Hopfner, M., Haider, K., Spona, J., Ludwig, H., and Pirker, R. MDR1 gene expression and prognostic factors in primary breast carcinomas. Eur. J. Cancer, 27: 1352-1355, 1991.
8. Ro, J., Sahin, A., Ro, J. Y., Fritsche, J., Hortobagyi, G., and Blick, M. Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy response in locally advanced breast cancer. Hum. Pathol., 21: 787-791, 1990.
9. Verrelle, P., Meissonnier, F., Fonck, Y., Feillei, V., Dionet, C., Kwiatkowski, F., Plagne, R., and Chassagne, J. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J. Natl. Cancer Inst., 83: 111-116, 1991.
10. Sanfilippo, O., Ronchmi, E., DeMarco, C., DiFronzo, G., and Silvestrini, R. Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Eur. J. Cancer, 7: 155-158, 1991.
11. Kieth, W. N., Stallard, S., and Brown, R. Expression of mdr1 and gst II in human breast tumors: comparison to in vitro chemosensitivity. Br. J. Cancer, 61: 712-716, 1990.
12. Goldstein, L. J., Galski, H., Fojo, A., Willingaham, M., Lai, S. L., Pirker, R., Green, A., Crist, W., and Brodeur, G. M. Expression of a human multidrug resistance gene in human cancers. J. Natl. Cancer Inst., 81: 116-124, 1989.
13. Uziely, B., Delaflor-Weiss, E., Lenz, H. J., Groshen, S., Jeffers, S., Watkins, K., Danenberg, K., Russell, C., Leichman, G., and Muggia, F. Paclitaxel in refractory breast cancer: response correlates with low levels of MDR1 gene expression. Proc. Am. Soc. Clin. Oncol., 13: 75, 1994.
14. Twentyman, P. R., and Bleehen, N. M. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporine. Eur. J. Cancer, 27: 1639-1642, 1991.
15. Bartlett, N. L., Lum, B. L., Fisher, G. A., Brophy, N. A., Ehsan, M. N., Halsey, J., and Sikic, B. I. Phase I trial of doxorubicin with cyclosporine as a modulator of drug resistance. J. Clin. Oncol., 12: 835-842, 1994.
16. Ferry, D. R., Traunecker, H., and Kerr, D. J. Clinical trials of P-glycoprotein reversal in solid tumors. Eur. J. Cancer, 32A: 1070-1081, 1996.
17. Fisher, G. A., Lum, J., Hausdorff, J., and Sikic, B. I. Pharmacologic considerations in the modulation of multidrug resistance. Eur. J. Cancer, 32A: 1082-1088, 1996.
18. Huizing, M. T., Misser, V. H., Pieters, R. C., ten Bokkel Huinink, W. W., Veenhof, C. H., Vermorken, J. B., Pinedo, H. M., and Beijnen, J. H. Taxanes: a new class of antitumor agents. Cancer Invest., 13: 381-404, 1995.
19. Ten Bokkel Huinink, W. W., van Oosterom, A. T., Piccart, M., Franklin, H., Wanders, J., Bayssas, M., and Kaye, S. B. Taxotere in advanced breast cancer; a Phase II trial of the EORTC Early Clinical Trials Group. Proc. Am. Soc. Clin. Oncol., 12: 37, 1993.
20. Reichman, B. S., Seidman, A. D., Crown, J. P. A., Heelan, R., Yao, T. J., Lebwohl, D. E., Gileski, T. A., Surbone, A., and Currie, V. Paclitaxel and recombinant human granulocyte colony stimulating factor as initial chemotherapy for metastatic breast cancer. J. Clin. Oncol., 11: 1943-1951, 1993.
21. Seidman, A. D., Reichman, B. S., Crown, J. P. A., Yao, T. J., Currie, V., Hakes, T. B., Hudis, C. A., Gileski, T. A., Baselga, J., and Forsythe, P. Paclitaxel as second and subsequent chemotherapy for metastatic breast cancer: activity independent of prior anthracycline response. J. Clin. Oncol., 13: 1152-1159, 1995.
22. Roy, S. N., and Horowitz, S. B. A phosphoglycoprotein associated with Taxol resistance in J744.2 cells. Cancer Res., 45: 3856-3863, 1985.
23. Gan, Y. B., Balturshot, G., Millenbaughm, N. J., Chen, C. T., Kalns, J. E., Lim, C., Wientjes, M. G., and Au, J. L. S. P-Glycoprotein expression in human tumors and its correlation with chemosensitivity to Taxol and cell mobility. Proc. Am. Assoc. Cancer Res., 36: 334, 1995.
24. Beck, T. W., Grogan, T. M., Willman, C. L., Cordon-Cardo, C., Parham, D. M., Kuttesch, J. F., Andreeff, M., Bates, S. E., Berard, C. W., Boyett, J. M., Brophy, N. A., Broxterman, H. J., Chan, H. S. L., Dalton, W. S., Dietel, M., Fojo, A. T., Gascoyne, R. D., Head, D., Houghton, P. J., Srivastava, D. K., Lehnert, M., Leith, C. P., Paietta, E., Pavelic, Z. P., Rimsza, L., Roninson, I. B., Sikic, B. I., Twentyman, P. R., Warnke, R., and Weinstein R. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res., 56: 3010-3020, 1996.
25. Goldstein, L. J. MDR1 gene expression in solid tumors. Eur. J. Cancer, 32A: 1039-1050, 1996.
26. Broxterman, H. J., Lankelma, J., and Pinedo, H. M. How to probe clinical samples for P-glycoprotein and multidrug resistance-associated protein. Eur. J. Cancer, 32A: 1024-1033, 1996.
27. Kern, D. H., and Weisenthal, L. M. Highly specific prediction of antineoplastic drag resistance with an in vitro assay using suprapharmacologic drug exposures. J. Natl. Cancer Inst., 82: 582-588, 1990.
28. Fruehauf, J. P., and Bosanquet, A. G. In vitro determination of drug response: a discussion of clinical applications. PPO Updates, 7: 1-16, 1993.
29. Mechetner, E. B., Schott, B., Morse, B. S., Stein, W. D., Druley, T., Davis, K. A., Tsuruo, T., and Roninson, I. B. P-Glycoprotein function involves conformational transitions detectable by differential immunoreactivity. Proc. Natl. Acad. Sci. USA, 94: 12908-12913, 1997.
30. Mechetner, E. B., and Roninson, I. B. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc. Natl. Acad. Sci. USA. 89: 5824-5828, 1992.
31. Fruehauf, J. P., and Sinha, B. K. Selective formation of tumor necrosis factor-α (TNF) degradation products contributes to TNF mediated cytotoxicity. Oncol. Res., 4: 91-101, 1992.
32. Fruehauf, J. P., and Manetta, A. Use of the extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: Taxol resistance and MDR-1 expression. Contrib. Gynecol. Obstet., 19: 39-52, 1994.
33. Arceci, R. J., Steiglitz, K., and Coop, J. M. A monoclonal antibody to an external epitope of the P-glycoprotein. Proc. Am. Assoc. Cancer Res., 33: 471, 1992.
34. Krishan, A., Sauerteig, A., and Stein, J. H. Comparison of three commercially available antibodies for flow cytometric monitoring of p-glycoprotein expression in tumor cells. Cytometry, 12: 731-742, 1991.
35. Gheuens, E. E. O., van Bockstaele, D. R., van der Keur, M., Tanke, H. J., van Oosterom, A. T., and De Bruijn, E. A. Flow cytometric double labeling technique for screening of multidrug resistance. Cytometry, 12: 636-644, 1991.
36. Sheehan, D. C., and Hrapchak, B. B. Theory and Practice of Histotechnology, 2nd ed. St. Louis: C. V. Mosby Co., 1980.
37. Bacus, S. S., and Ruby, S. G. Application of image analysis to the evaluation of cellular prognostic factors in breast carcinoma. Pathol. Annu., 28: 179-204, 1993.
38. Scheper, R. J., Bulte, J. W. M., Brakkee, J. G. P., Quak, J. J., van der School, E., Balm, A. J., Meijer, C. J., Broxterman, H. J., Kuiper, C. M., and Lankelma, J. Monoclonal antibody JSB-1 detects a highly conserved epitope on the p-glycoprotein associated with multi-drug resistance. Int. J. Cancer, 42: 389-394, 1988.
39. Lieth, C., Chen, I., Kopecky, K., Appelbaum, F. R., Head, D. R., Godwin, J. E., Weick, J. K., and Willman, C. L. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR+/efflux-cases. Blood, 86: 2329-2342, 1995.
40. Cowan, K. H., Batist, G., Tulpule, A., Sinha, B. K., and Myers, C. E. Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc. Natl. Acad. Sci. USA, 83: 9328-9332, 1986.
41. Chaudhary, P. M., and Roninson, I. B. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J. Natl. Cancer Inst., 85: 632-639, 1993.
42. Cummisky, R. D., Kyshtoobayeva, A., Garcia, R., Fruehauf, J. P., Mechetner, E., and Levine, E. The effect of preoperative chemotherapy on MDR1 and MRP expression in the patients with locally advanced breast carcinoma. Proc. Soc. Surg. Oncol., 41: 26, 1997.